On February 11, 2022 Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, reported that company management will participate in Citi’s 2022 Immuno-Oncology Summit (Press release, Sensei Biotherapeutics, FEB 11, 2022, View Source [SID1234608030]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Robert Pierce, Chief R&D Officer, will participate in a fireside chat beginning at 2:30pm ET on Wednesday, February 16, 2022. A webcast of the fireside chat will be available on the Events & Presentations section of Sensei’s website at www.senseibio.com. A replay of the webcast will be on the website for approximately 90 days following the event.